Table 3.

CD11b and CD18 expression at the surface of resting and fMLP-stimulated PMNs from controls and patients

SubjectsMFI
Unstimulated PMNsfMLP-stimulated PMNs
CD11bCD18CD11bCD18
African controls (n = 11) 242 ± 30 47 ± 4 2957 ± 130 333 ± 23 
Non-VOC group (n = 15) 226 ± 22 49 ± 5 2356 ± 1483-150 240 ± 253-150 
VOC group (n = 17) 227 ± 15 44 ± 3 2545 ± 160 266 ± 173-150 
HU group (n = 9) 247 ± 40 49 ± 3 2425 ± 1603-150 259 ± 193-150 
SubjectsMFI
Unstimulated PMNsfMLP-stimulated PMNs
CD11bCD18CD11bCD18
African controls (n = 11) 242 ± 30 47 ± 4 2957 ± 130 333 ± 23 
Non-VOC group (n = 15) 226 ± 22 49 ± 5 2356 ± 1483-150 240 ± 253-150 
VOC group (n = 17) 227 ± 15 44 ± 3 2545 ± 160 266 ± 173-150 
HU group (n = 9) 247 ± 40 49 ± 3 2425 ± 1603-150 259 ± 193-150 

Whole blood was incubated with anti-CD11b and anti-CD18 antibodies at 4°C for 30 minutes, either after maintaining the samples at 4°C (unstimulated PMNs) or after incubation with PBS or fMLP (10−6 M) at 37°C for 5 minutes. The MFI was recorded as described in “Patients, materials, and methods.” Values are given as means ± SEM.

F3-150

Significantly different from controls (P < .05).